SiteOne has received significant investment after years of small grant funding, indicating renewed interest in their approach to pain management.
Founders
John Mulcahy
Company Description
SiteOne Therapeutics is focused on developing non-addictive pain drugs by targeting ion channels in peripheral nerve cells. The company aims to obtain proof of concept for its medicines through human studies.
Market
Non-opioid pain medications
Location
USA
Coinvestors
Novo Holdings, OrbiMed, Wellington Management, Mission BioCapital, BSquared Capital